08.24.16
Metrics Contract Services is investing $3.5 million in a 15,000-sq.-ft. stability storage expansion at its Greenville campus that will triple current capacity. The company has seen growth of clients’ registration batch stability programs in support of various international markets.
Scheduled to open Spring of 2017, the expanded stability storage facility will feature large, walk-in chambers with state-of-the-art controls, system redundancies and back-up power supply to ensure integrity of stored samples.
Metrics will also introduce commercial-scale manufacturing capability including multi-particulate layering, bead-coating fluid bed technology and significantly increased capacity to manufacture highly potent products.
John S. Ross, executive vice president, said, “As a full-service, global drug development and manufacturing organization, Metrics is committed to ensuring we adequately support client’s needs throughout their product’s life cycle, and providing sufficient, reliable stability services is one way we do that,” he said. “Our goal is to become the oral-dose ‘concept to commercialization’ CDMO of choice for pharma companies, and our larger stability storage capacity represents part of that commitment to meet client needs.”
Additionally, Metrics’ parent company, Mayne Pharma, is investing $80 million to significantly expand facilities and equipment, including 10-plus new analytical labs and formulation development suites.
Metrics and Mayne Pharma plan to hire 110 new scientists, quality assurance specialists and other technicians to support expanded operations.
Scheduled to open Spring of 2017, the expanded stability storage facility will feature large, walk-in chambers with state-of-the-art controls, system redundancies and back-up power supply to ensure integrity of stored samples.
Metrics will also introduce commercial-scale manufacturing capability including multi-particulate layering, bead-coating fluid bed technology and significantly increased capacity to manufacture highly potent products.
John S. Ross, executive vice president, said, “As a full-service, global drug development and manufacturing organization, Metrics is committed to ensuring we adequately support client’s needs throughout their product’s life cycle, and providing sufficient, reliable stability services is one way we do that,” he said. “Our goal is to become the oral-dose ‘concept to commercialization’ CDMO of choice for pharma companies, and our larger stability storage capacity represents part of that commitment to meet client needs.”
Additionally, Metrics’ parent company, Mayne Pharma, is investing $80 million to significantly expand facilities and equipment, including 10-plus new analytical labs and formulation development suites.
Metrics and Mayne Pharma plan to hire 110 new scientists, quality assurance specialists and other technicians to support expanded operations.